These data demonstrate that (i) the presence of an ALK mutation may not always provide selective advantage in neuroblastoma, and (ii) the mutation with the putatively highest oncogenic potential F1174L [11] does not necessarily prevail over the R1275Q mutation, both under conventional treatment and ALK inhibitor therapy. This evidence concerns the gene ALK and neuroblastoma.